3 citations
,
February 2023 in “BMJ Case Reports” This case report describes a woman with trichotillomania who experienced marked improvement and hair regrowth after off-label onabotulinumtoxinA treatment.
June 2023 in “Lithuanian University of Health Sciences” May 2022 in “Journal of Neurology Neurosurgery & Psychiatry” In this study, 81% of patients with chronic migraine in Glasgow continued using erenumab for significant headache reduction at three months, suggesting a high response rate.
January 2007 in “UNIFESP Institutional Repository (Universidade Federal de São Paulo)” This study found that patients with chronic migraine who excessively use symptomatic medications had a higher prevalence of anxiety and mood disorders, suggesting these psychiatric diagnoses may influence medication overuse.
December 2025 in “Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)” In this review, researchers examined nine studies on botulinum toxin type A's effects on biomarkers in chronic head and neck conditions, finding significant, though low to moderate certainty, changes in markers like CGRP and serotonin associated with inflammation and mood disorders.